drugset / Trial / NCT03549832

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

NCT03549832

RandomizedParallel-groupOpen-labelTreatment

Summary

Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/ paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.

Timeline

Start
2018-01-01
Primary completion
2019-01-30
Completion
2019-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daclatasvir Small molecule 60 mg Oral
Comparator Ombitasvir/paritaprevir/ritonavir Unknown Oral
Comparator Simeprevir Small molecule 150 mg Oral
Comparator Ribavirin Small molecule 200 mg Oral
Comparator Sofosbuvir Small molecule 400 mg Oral